Inhibition of BET proteins and histone deacetylase (HDACs): Crossing roads in cancer therapy

Gloria Manzotti, Alessia Ciarrocchi, Valentina Sancisi

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Histone DeACetylases (HDACs) are enzymes that remove acetyl groups from histones and other proteins, regulating the expression of target genes. Pharmacological inhibition of these enzymes re-shapes chromatin acetylation status, confusing boundaries between transcriptionally active and quiescent chromatin. This results in reinducing expression of silent genes while repressing highly transcribed genes. Bromodomain and Extraterminal domain (BET) proteins are readers of acetylated chromatin status and accumulate on transcriptionally active regulatory elements where they serve as scaffold for the building of transcription-promoting complexes. The expression of many well-known oncogenes relies on BET proteins function, indicating BET inhibition as a strategy to counteract their activity. BETi and HDACi share many common targets and affect similar cellular processes to the point that combined inhibition of both these classes of proteins is regarded as a strategy to improve the effectiveness of these drugs in cancer. In this work, we aim to discuss the molecular basis of the interplay between HDAC and BET proteins, pointing at chromatin acetylation as a crucial node of their functional interaction. We will also describe the state of the art of their dual inhibition in cancer therapy. Finally, starting from their mechanism of action we will provide a speculative perspective on how these drugs may be employed in combination with standard therapies to improve effectiveness and/or overcome resistance.

Original languageEnglish
Article number304
JournalCancers
Volume11
Issue number3
DOIs
Publication statusPublished - Mar 1 2019

Fingerprint

Histone Deacetylases
Chromatin
Acetylation
Neoplasms
Gene Expression
Enzymes
Therapeutics
Oncogenes
Pharmaceutical Preparations
Histones
Proteins
Pharmacology
Protein Domains
Genes

Keywords

  • BET protein
  • Cancer
  • Combination therapy
  • Epigenetic drugs
  • HDAC
  • Histone modifications

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Inhibition of BET proteins and histone deacetylase (HDACs) : Crossing roads in cancer therapy. / Manzotti, Gloria; Ciarrocchi, Alessia; Sancisi, Valentina.

In: Cancers, Vol. 11, No. 3, 304, 01.03.2019.

Research output: Contribution to journalReview article

@article{d1a644c4787f4de9b4cc3c5809f753b9,
title = "Inhibition of BET proteins and histone deacetylase (HDACs): Crossing roads in cancer therapy",
abstract = "Histone DeACetylases (HDACs) are enzymes that remove acetyl groups from histones and other proteins, regulating the expression of target genes. Pharmacological inhibition of these enzymes re-shapes chromatin acetylation status, confusing boundaries between transcriptionally active and quiescent chromatin. This results in reinducing expression of silent genes while repressing highly transcribed genes. Bromodomain and Extraterminal domain (BET) proteins are readers of acetylated chromatin status and accumulate on transcriptionally active regulatory elements where they serve as scaffold for the building of transcription-promoting complexes. The expression of many well-known oncogenes relies on BET proteins function, indicating BET inhibition as a strategy to counteract their activity. BETi and HDACi share many common targets and affect similar cellular processes to the point that combined inhibition of both these classes of proteins is regarded as a strategy to improve the effectiveness of these drugs in cancer. In this work, we aim to discuss the molecular basis of the interplay between HDAC and BET proteins, pointing at chromatin acetylation as a crucial node of their functional interaction. We will also describe the state of the art of their dual inhibition in cancer therapy. Finally, starting from their mechanism of action we will provide a speculative perspective on how these drugs may be employed in combination with standard therapies to improve effectiveness and/or overcome resistance.",
keywords = "BET protein, Cancer, Combination therapy, Epigenetic drugs, HDAC, Histone modifications",
author = "Gloria Manzotti and Alessia Ciarrocchi and Valentina Sancisi",
year = "2019",
month = "3",
day = "1",
doi = "10.3390/cancers11030304",
language = "English",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI AG",
number = "3",

}

TY - JOUR

T1 - Inhibition of BET proteins and histone deacetylase (HDACs)

T2 - Crossing roads in cancer therapy

AU - Manzotti, Gloria

AU - Ciarrocchi, Alessia

AU - Sancisi, Valentina

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Histone DeACetylases (HDACs) are enzymes that remove acetyl groups from histones and other proteins, regulating the expression of target genes. Pharmacological inhibition of these enzymes re-shapes chromatin acetylation status, confusing boundaries between transcriptionally active and quiescent chromatin. This results in reinducing expression of silent genes while repressing highly transcribed genes. Bromodomain and Extraterminal domain (BET) proteins are readers of acetylated chromatin status and accumulate on transcriptionally active regulatory elements where they serve as scaffold for the building of transcription-promoting complexes. The expression of many well-known oncogenes relies on BET proteins function, indicating BET inhibition as a strategy to counteract their activity. BETi and HDACi share many common targets and affect similar cellular processes to the point that combined inhibition of both these classes of proteins is regarded as a strategy to improve the effectiveness of these drugs in cancer. In this work, we aim to discuss the molecular basis of the interplay between HDAC and BET proteins, pointing at chromatin acetylation as a crucial node of their functional interaction. We will also describe the state of the art of their dual inhibition in cancer therapy. Finally, starting from their mechanism of action we will provide a speculative perspective on how these drugs may be employed in combination with standard therapies to improve effectiveness and/or overcome resistance.

AB - Histone DeACetylases (HDACs) are enzymes that remove acetyl groups from histones and other proteins, regulating the expression of target genes. Pharmacological inhibition of these enzymes re-shapes chromatin acetylation status, confusing boundaries between transcriptionally active and quiescent chromatin. This results in reinducing expression of silent genes while repressing highly transcribed genes. Bromodomain and Extraterminal domain (BET) proteins are readers of acetylated chromatin status and accumulate on transcriptionally active regulatory elements where they serve as scaffold for the building of transcription-promoting complexes. The expression of many well-known oncogenes relies on BET proteins function, indicating BET inhibition as a strategy to counteract their activity. BETi and HDACi share many common targets and affect similar cellular processes to the point that combined inhibition of both these classes of proteins is regarded as a strategy to improve the effectiveness of these drugs in cancer. In this work, we aim to discuss the molecular basis of the interplay between HDAC and BET proteins, pointing at chromatin acetylation as a crucial node of their functional interaction. We will also describe the state of the art of their dual inhibition in cancer therapy. Finally, starting from their mechanism of action we will provide a speculative perspective on how these drugs may be employed in combination with standard therapies to improve effectiveness and/or overcome resistance.

KW - BET protein

KW - Cancer

KW - Combination therapy

KW - Epigenetic drugs

KW - HDAC

KW - Histone modifications

UR - http://www.scopus.com/inward/record.url?scp=85063388232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063388232&partnerID=8YFLogxK

U2 - 10.3390/cancers11030304

DO - 10.3390/cancers11030304

M3 - Review article

AN - SCOPUS:85063388232

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 3

M1 - 304

ER -